Nuvectis Pharma Reports NMPA Approval of Ciprocopan for Paroxysmal Nocturnal Hemoglobinuria (PNH)

Shots: The NMPA has approved ciprocopan (NXP100, QD, PO) for the treatment of pts with PNH previously untreated with Complement inhibitors. Application for PNH pts previously treated with anti-C5 therapies is under review in China Approval was based on a P-III trial of ciprocopan vs Soliris in the above-mentioned pts, which met all 1 &…

ByRidhi RastogiJuly 24, 2026

NEWS

Teva and Samsung Bioepis Launch Epysqli (Biosimilar, Soliris) in the US

Shots: Teva & Samsung Bioepis have launched Epysqli, a biosimilar version of Soliris (eculizumab) in the US to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) & generalized myasthenia gravis(gMG) in AchR antibody-positive adults Epysqli was approved by the US FDA in Jul 2024 for PNH & aHUS, with a label expansion to gMG in…

ByRidhi RastogiApril 8, 2025

Nuvectis Pharma Reports NMPA Approval of Ciprocopan for Paroxysmal Nocturnal Hemoglobinuria (PNH)

Teva and Samsung Bioepis Launch Epysqli (Biosimilar, Soliris) in the US

Contact US

FOLLOW US